https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46451 Wed 23 Nov 2022 14:17:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41167 Wed 21 Jun 2023 15:55:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37416 Wed 18 Nov 2020 09:52:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36268 Wed 18 Mar 2020 14:05:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27319 Wed 11 Apr 2018 15:35:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27318 Wed 11 Apr 2018 14:21:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29423 Wed 11 Apr 2018 11:56:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13830 Tue 24 Aug 2021 14:29:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33707 Thu 13 Jan 2022 10:32:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35398 0.05), and similar pulmonary and extrapulmonary characteristics. The associations between extrapulmonary variables and HRQoL did not differ according to diagnosis (all interactions p > 0.05). Greater anxiety and depressive symptoms, fewer steps/day and greater systemic inflammation were statistically associated with poorer HRQoL in both diseases (p < 0.05). Lower isometric leg strength in severe asthma, and greater Charlson Comorbidity Index in bronchiectasis were also associated with poorer HRQoL (p < 0.05). In the multivariable regression model performed in the combined disease groups, anxiety and depression, steps/day, systemic inflammation and isometric leg strength remained independently associated with HRQoL. Associations between extrapulmonary characteristics and SGRQ domains were stronger for the activity and impact domains, than symptoms. Conclusion: In severe asthma and bronchiectasis, extrapulmonary features including physical activity and leg strength have a significant impact on HRQoL, especially within the activity and impact domains. These features should be considered as part of the assessment of these conditions, and they may represent additional treatment targets to improve HRQoL.]]> Thu 09 Dec 2021 11:03:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49876 3 mg/L), and depression. In both trials, TT treatment led to a large, significant improvement in HRQOL compared with usual care (Cohen's d = 1.19; P < .001). Receiving a statin for systemic inflammation and oral corticosteroid for eosinophilic airway inflammation was associated with the largest HRQOL improvements. Treatments for exercise intolerance, anxiety, and obesity were associated with smaller improvements in HRQOL. Conclusions: This study contributes to identifying clinically impactful TTs by showing that TTs across pulmonary, extrapulmonary, and behavioral domains were associated with HRQOL impairment and treatment response.]]> Thu 08 Jun 2023 15:21:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40274 Thu 07 Jul 2022 12:58:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32622 Thu 03 Feb 2022 12:18:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17701 Sat 24 Mar 2018 07:57:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19175 Sat 24 Mar 2018 07:52:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29253 N = 2,776; 18–65 years; 66% female). At baseline, 2- and 6-year follow-up, participants completed diagnostic interviews, depression and anxiety symptom inventories, antidepressant use assessment, and measurements of the five metabolic syndrome components. Data were analyzed for the consistency of associations between psychopathology indicators and metabolic syndrome components across the three assessment waves, and whether psychopathology or antidepressant use at one assessment predicts metabolic dysregulation at the next and vice versa. Results: Consistently across waves, psychopathology was associated with generally poorer values of metabolic syndrome components, particularly waist circumference and triglycerides. Stronger associations were observed for psychopathology symptom severity than diagnosis. Antidepressant use was independently associated with higher waist circumference, triglycerides and number of metabolic syndrome abnormalities, and lower HDL-C. Symptom severity and antidepressant use were associated with subsequently increased number of abnormalities, waist circumference, and glucose after 2 but not 4 years. Conversely, there was little evidence that metabolic syndrome components were associated with subsequent psychopathology outcomes. Conclusions: Symptom severity and antidepressant use were independently associated with metabolic dysregulation consistently over time and also had negative consequences for short-term metabolic health. This is of concern given the chronicity of depression and anxiety and prevalence of antidepressant treatment.]]> Sat 24 Mar 2018 07:39:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25923 Sat 24 Mar 2018 07:27:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37810 Mon 31 Jan 2022 15:14:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41270 Mon 01 Aug 2022 09:49:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49505 Fri 19 May 2023 14:07:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37892 Fri 01 Apr 2022 09:25:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36583 Fri 01 Apr 2022 09:23:30 AEDT ]]>